Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2020

View Archived Issues

Transplanted iPSCs are best of both ApoE models

Keros completes dosing of planned cohorts in phase I study of KER-047

Oral RECCE-435 shows efficacy in animal model of H. pylori infection

Huya Bioscience obtains worldwide rights to SHP-2 inhibitor

IBC-Ab002 shows promising safety and efficacy in models of AD

p53 plays role of Dr. Jekyll or Mr. Hyde in gastric cancer

Betta Pharmaceuticals divulges EGFR mutant inhibitors

Merck & Co. discloses new compounds for tuberculosis

Chinese researchers present new mu-opioid receptor agonists

New HER2 inhibitors presented by Taiho Pharmaceutical

Voronoi patent details RIP-1 inhibitors

IMV receives funding for phase I study of DPX-COVID-19 vaccine

MODAG completes first phase I study of Anle-138b

Revive finalizing details for phase III study of bucillamine in COVID-19

HTA presents new prostate cancer diagnosis probe [68Ga]DOTA-ANCP-PSMA

Positive preliminary data presented from diverticulosis pilot trial of PGLG

Personalized TLPLDC vaccine demonstrates long-term survival benefit in high-risk melanoma

Phase III study of CS-1001 as first-line treatment of NSCLC meets primary endpoint

Genetic variant in IFITM3 gene tied to disease severity in COVID-19 disease

FDA approves Blenrep for relapsed or refractory multiple myeloma

Lundbeck discontinues phase II study of Lu-AF-11167

Phase II study of BioAegis' gelsolin for COVID-19 begins in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...